2023 Fiscal Year Annual Research Report
Needle-free microfluidic vaccine/drug delivery
| Project/Area Number |
21H01253
|
|---|
| Allocation Type | Single-year Grants |
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
ホサノ ハミド 熊本大学, 産業ナノマテリアル研究所, 教授 (00543406)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
秀 拓一郎 北里大学, 医学部, 准教授 (40421820)
|
|---|
| Project Period (FY) |
2021-04-01 – 2025-03-31
|
| Keywords | ワクチン/ドラッグデリバリー / マイクロフルイディクス / バイオエンジニアリング |
|---|
| Outline of Annual Research Achievements |
The goal of the research for fiscal year 2023 (R 5) was defined as experimental evaluation and analysis of novel nanosecond pulsed discharge induced cavitation/shock wave micro-jets; quantitative in-vitro, ex-vivo, and in-vivo assessment; and publication.
According to the plan, new innovative models have been designed to minimize possibility of electrodes damage after pulse discharges, which could considerably improve durability of the microjet device. Real-time ultra-high-speed flow visualizations of micro-jets induced by different electrode configuration and energy models to control microjets penetration depth have been performed and the results were compared. Analysis of micro-jet shear stress induced poration in cell lines have been performed. Experimental and theoretical evaluation of how underwater shock waves and microstreaming can cause cell poration for effective vaccine/drug uptake have been carried. The results are discussed in a well-prepared manuscript. In order to refer to concern regarding possibility of any damage due to shock waves produced by the microjet injectors, we applied weak shock waves to glioblastoma cells and performed comprehensive gene expression analysis by using RNA-sequencing. The interesting results confirm the device is safe. We will continue the experiments to find the shock waves threshold to cause gene damage. Evaluation and optimization of the device based on the cells and ex-vivo results were performed. Preparation steps for in-vivo study and assessment of controlled release of vaccine and drug in mouse model have been performed.
|
| Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
The research has been progressing according to the plan. The goals for the year 2023 (R 5) have been achieved.
|
| Strategy for Future Research Activity |
Based on progress achieved during year 2023 (R 5), measures have been taken for the research to advance as planned. Further publication, international conference presentation, and international collaborations have been planned to advance the research.
|
